Cellebrite CFO plans USD 267,160 sale. Analysts target Cellebrite stock at USD 15.36

Published on 10/08/2026 at 17:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Seven analysts rate Cellebrite stock a Buy with USD 15.36 target. EUR 10.03 on October 8, 2026 follows EUR 10.00, plus 0.30 percent.

Key points in brief

CFO David Barter filed a planned sale of 23,497 shares worth USD 267,160.89 for October 16, 2026.
Seven analysts rate Cellebrite stock a Buy, with a consensus target of USD 15.36 as of October 7, 2026.
Q2 2026 revenue reached USD 131.14 million, while full-year revenue guidance stands at USD 555 million to USD 561 million.
The Lang & Schwarz price was EUR 10.03 on October 8, 2026, plus 0.30 percent versus EUR 10.00.

CLBT, IL0011794802, Illustration mit AI erstellt.

Cellebrite CFO David Barter planned to sell 23,497 ordinary shares worth USD 267,160.89 on October 16, 2026, according to StockTitan on October 7, 2026. The filing describes the transaction as a mandatory, non-discretionary sell-to-cover arrangement for taxes tied to restricted stock unit vesting.

What changed in the latest filing?

The proposed sale represents 0.01 percent of Cellebrite's 251,341,060 ordinary shares listed in the filing. That supply signal is limited in size, while the planned date gives investors a concrete event to track.

Three dated operating signals

On August 13, 2026, Cellebrite reported second-quarter revenue of USD 131.14 million, up 16 percent year over year, according to Yahoo Finance. The same quarter produced ARR of USD 508 million, up 21 percent, but it fell below the lower end of the prior guidance range.

On August 13, 2026, management set full-year 2026 revenue guidance at USD 555 million to USD 561 million, representing growth of 17 percent to 18 percent, and lifted adjusted EBITDA guidance to USD 153 million to USD 159 million. On October 7, 2026, the Form 144 filing added the planned USD 267,160.89 tax-cover sale as the latest dated event.

What does the target imply?

StockUpside listed a consensus target of USD 15.36 on October 7, 2026, with seven analysts covering the stock and a Buy consensus. Against its cited USD 11.37 reference price, that target implies 35.09 percent upside, calculated from the two dollar values.

Dates investors can track

The planned CFO sale is dated October 16, 2026. A separate provider estimate places Cellebrite's next earnings date on November 10, 2026, while the company's reported third-quarter outlook calls for revenue of USD 145 million to USD 148 million and adjusted EBITDA of USD 42 million to USD 45 million, according to Yahoo Finance.

Stock holds near EUR 10

Cellebrite stock was trading at EUR 10.03 at Lang & Schwarz on October 8, 2026 at 5:00 p.m. CEST, plus 0.30 percent versus the Lang & Schwarz prior close of EUR 10.00 on October 7, 2026. The primary listing is Nasdaq under ticker CLBT, and the finance quote showed a USD 2.8 billion market capitalization and a USD 9.58 to USD 19.98 52-week range as of October 8, 2026.

The further course of trading is shown by the continuously updated real-time quote of Cellebrite stock.